L’Oreal SA (0NZM)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 435.70 |
|---|---|
| 52-week range | 322.86 – 437.95 |
| Return, 1 month / 3 months | +14.1% / +15.2% |
| Return, 1 year / 3 years | +18.2% / +18.8% |
| Trend | Uptrend |
| RSI (14) | 80 |
| Volatility (1 year) | 24.8% |
| Worst drawdown (1 year) | -14.6% |
| Average daily value traded | 42.86M EUR |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
L'Oreal is a French cosmetics company based in Paris. It develops and markets skincare, haircare, makeup and fragrance products under a wide range of brand names, serving everyday consumers as well as professional salons and luxury shoppers around the world. Its products reach customers through mass-market retailers, pharmacies, department stores, travel retail and its own branded outlets, and the company also owns brands sold in professional hair salons.
On this site L’Oreal SA appears as a stock on the London Exchange (UK), code 0NZM, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
L’Oreal SA (0NZM) trades on the London Exchange in UK. It last closed at EUR 435.70 on 23 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 291 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 18.2% and over the last three months it rose 15.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.1% | ||
| From 52-week high | 0.0% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 15.2% | ||
| 6-month return | 18.0% | ||
| 12-month return, skipping the last month | 3.6% | ||
| Stability (higher is calmer) | 81 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.6% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 42.86M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 34 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +7.2% |
|---|---|
| 1 month | +14.1% |
| 3 months | +15.2% |
| 6 months | +18.0% |
| 1 year | +18.2% |
| 3 years | +18.8% |
| 5 years | +21.4% |
Signals
| 50-day / 200-day average | 385.87 / 375.33 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 8.99 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Apr 2026 | EUR 7.2000 |
| 2 May 2025 | EUR 7.0000 |
| 26 Apr 2024 | EUR 6.6000 |
| 26 Apr 2023 | EUR 6.0000 |
| 27 Apr 2022 | EUR 4.8000 |
| 27 Apr 2021 | EUR 4.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.